272,571 Shares in Adaptive Biotechnologies Corporation $ADPT Acquired by Polar Asset Management Partners Inc.

Polar Asset Management Partners Inc. acquired a new stake in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) during the 2nd quarter, Holdings Channel.com reports. The fund acquired 272,571 shares of the company’s stock, valued at approximately $5,847,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. BlackRock Inc. purchased a new stake in Adaptive Biotechnologies in the second quarter worth approximately $324,735,000. Ameriprise Financial Inc. increased its stake in shares of Adaptive Biotechnologies by 84.3% in the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock worth $89,337,000 after purchasing an additional 2,731,648 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Adaptive Biotechnologies by 303.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock valued at $71,252,000 after purchasing an additional 3,299,635 shares during the period. Westfield Capital Management Co. LP purchased a new position in shares of Adaptive Biotechnologies during the 4th quarter valued at $65,942,000. Finally, Geode Capital Management LLC boosted its stake in shares of Adaptive Biotechnologies by 3.3% in the fourth quarter. Geode Capital Management LLC now owns 3,511,855 shares of the company’s stock worth $57,041,000 after acquiring an additional 110,825 shares during the period. 99.17% of the stock is owned by institutional investors.

Insider Buying and Selling at Adaptive Biotechnologies

In other news, CEO Chad M. Robins sold 321,324 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $25.08, for a total value of $8,058,805.92. Following the sale, the chief executive officer owned 2,180,518 shares of the company’s stock, valued at approximately $54,687,391.44. This represents a 12.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Harlan S. Robins sold 492,400 shares of the firm’s stock in a transaction dated Tuesday, July 21st. The stock was sold at an average price of $21.89, for a total transaction of $10,778,636.00. Following the completion of the sale, the insider owned 812,058 shares of the company’s stock, valued at $17,775,949.62. This trade represents a 37.75% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 2,062,325 shares of company stock valued at $46,659,069. Insiders own 5.70% of the company’s stock.

Adaptive Biotechnologies Price Performance

Shares of Adaptive Biotechnologies stock opened at $26.25 on Wednesday. The stock has a market cap of $4.19 billion, a price-to-earnings ratio of -64.02 and a beta of 2.08. The company has a debt-to-equity ratio of 2.22, a quick ratio of 4.68 and a current ratio of 4.79. The stock has a 50 day moving average price of $22.40 and a 200-day moving average price of $17.45. Adaptive Biotechnologies Corporation has a one year low of $12.00 and a one year high of $26.49.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings results on Wednesday, July 29th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.12). The company had revenue of $71.55 million for the quarter, compared to analysts’ expectations of $65.44 million. Adaptive Biotechnologies had a negative net margin of 20.73% and a negative return on equity of 36.81%. The business’s quarterly revenue was up 21.5% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.17) EPS. Equities analysts expect that Adaptive Biotechnologies Corporation will post -0.4 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Morgan Stanley lifted their target price on Adaptive Biotechnologies from $20.00 to $22.00 and gave the stock an “equal weight” rating in a report on Thursday, July 30th. BTIG Research raised their price target on Adaptive Biotechnologies from $24.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, July 30th. TD Cowen lifted their price objective on Adaptive Biotechnologies from $25.00 to $28.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Friday, July 17th. Finally, JPMorgan Chase & Co. decreased their price objective on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Adaptive Biotechnologies presently has an average rating of “Moderate Buy” and an average price target of $24.42.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.